|Videos|December 13, 2021
Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.
Advertisement
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how the results of a longer term study differ for individuals who were younger as opposed to those who are older.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Calcium Gap: How Pharmacists Can Guide Patients Toward Better Bone Health
2
COVID-19 Vaccination in Medically Complex Adults
3
Testing categories in practice — clinical conversations
4
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
5